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Ditopic Hexadentate Ligands with a Central Dihydrobenzo-
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Manfred M. Kappes,[a, c] and Mario Ruben*[a, d, e]
A family of ditopic hexadentate ligands based on the parent
compound 2,6-bis(6-(pyrazol-1-yl)pyridin-2-yl)-1,5-dihydrobenzo
[1,2-d:4,5-d’]diimidazole (L) was developed and synthesized by
using a straightforward condensation reaction, which forms the
interlinking central benzo[1,2-d:4,5-d’]diimidazole bridge in the
ligand backbone. The two secondary amine groups of the
benzodiimidazole unit tautomerize and allow the formation of
two tauto-conformers, which upon treatment with metal salts
forms different isomeric coordination complexes. Here we
report six new derivatives (1–6) that can tautomerize (varying
the pyrazolylpyridine part) and 14 derivatives (7–13) with
different alkyl and benzyl substitution on secondary amino
groups (of L) that prevent the tautomerization. This way, it is
possible to study the properties of isomeric coordination
complexes and their intrinsic cooperativity by the example of
[2x2] grid complexes in the future. A [2x2] Zn4 complex of the
ligand L was synthesized and structurally characterized.
Introduction
Ditopic ligands are of continuing interest to the covalent
integration of metal ions into molecular metal complexes.[1]
Such ligands with at least two metal-binding domains can be
used to synthesize homo and hetero multi-metallic complexes
such as metal-containing supramolecular and macromolecular
species (polymers, dendrimers, molecular wires) and oligonu-
clear grid type metal complexes.[2–5] If the coordination sites of
ditopic ligands differ in their metal-chelating properties,
discrimination by means of optimized synthetic protocols can
yield hetero-metallic complexes.[6,7] The resulting complexes
feature different catalytic, magnetic, and photophysical proper-
ties and may enable new cooperative functionality.[8–12] In this
context, a number of bimetallic complex catalysts have been
reported, e.g., in asymmetric allylic alkylation,[13] water
oxidation,[14–18] epoxidation,[19] and transfer hydrogenation of
ketones.[20] The probably most adaptable and established
ligands for this purpose are derivatives of 2,2’:6’,2“-terpyridine
(terpy) type containing, inter alia, pyrazole, tetrazole, and
imidazole subunits.[21–29]
Whereas a number of ligands with tridentate chelates and
tautomeric subunits have been described previously,[25,30,31,32,33]
we are not aware of any examples that describe the presence of
different tauto-conformers and the parallel formation of
isomeric reaction products upon coordination to transition
metal ions.
Recently, we reported on a homoditopic ligand L, which
consists of two tridentate 2-(1H-imidazol-2-yl)-6-(pyrazol-1-yl)
pyridine units interlinked via a central benzo[1,2-d:4,5-d’]
diimidazole bridge (red, Figure 1a).[34] This bridging unit can
simultaneously undergo two tautomerization processes be-
tween a secondary amine and imine functional groups. Besides,
conformational isomers can be formed by rotation about the
single bonds between the aromatic ring systems in the back-
bone of the ligand (Figure 1a). The rotational barriers of the
single bonds connecting the pyridine and imidazole subunits
enable two in-plane conformations, so-called S and C conforma-
tions (this denomination arises from their apparent shape, see
Figure 1c). These two conformations are stabilized by the
interaction between the N-based lone pair electrons and the H
atoms of the neighboring aromatic rings (see Figure 1b).
The investigation of a solution sample of L by 1H NMR
spectroscopy revealed that both tauto-conformers are present
in the solution and the LS:LC ratio of one was estimated from
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NMR studies in (deuterated) DMSO. Both tauto-conformers, LS
and LC, can coordinate with metal ions in two tridentate
binding pockets.
The different chelating modes of the homoditopic ligand L
were read out by coordination with FeII ions. This read-out took
place in parallel, and multiple coordination products differing in
their structures and properties have been observed.[34] Among
them, the two dominant, isomeric tauto-conformers [Fe4(LS)4]
8+
and [Fe4(LC)4]8+ of the [2x2] FeII4 grid-type complexes were
isolated as crystals by several steps of fractional
crystallization.[34,35,36]
In the present work, we describe the synthesis, structures,
and properties of some members of this new ligand family with
respect to the substitution at the periphery and also to the
central part of the ligand backbone, so that the ligands could
not tautomerize; thus parallel product formation can be
avoided. Here, we also present a coordination complex with
Zn2+ metal ions and describe its properties.
Results and Discussion
The tauto-isomerization processes of the ligands and the
formed complexes are interesting in themselves and may give
insights regarding the general mechanisms of such tauto-
isomerization processes. In the following, we will discuss the
synthesis of six new ligands with a free NH group at the
imidazole subunit but differing in their aromatic backbone. The
intrinsic electronic and steric properties of ligand L can be easily
adapted, which is apparent from the synthetic procedure
shown in Scheme 1. The last step in the ligand synthesis is the
condensation reaction of a carboxylic acid derivative (C) and a
half equivalent of 1,2,4,5-benzenetetramine tetrahydrochloride
in polyphosphoric acid (PPA). The character of the peripheral
aromatic rings in the ligand can be determined in the synthetic
step (a), where a suitable pyrazole derivative can be chosen
(see R: 1–4 in Scheme 1). In the case of a peripheral pyridine
substitution, as shown for 5 and 6, we employed the respective
[2,2’-bipyridine]-6-carboxylic acid, which was prepared either
from 2,2’-bipyridine or 6’-methyl-[2,2’-bipyridine]-6-carboxylic
acid in two steps. The final condensation reaction between the
carboxylic acid derivative and benzene tetraamine in polyphos-
phoric acid (PPA) forms the respective ligand (1–6) in good
yields.
The synthesized ligands 1 to 6 were entirely characterized
by standard methods like 1H and 13C NMR spectroscopy, mass
spectrometry, and elemental analysis. It was possible to
determine the molecular structure of 3 and 5 by X-ray
diffraction of single crystals crystallized from deuterated DMSO
with a drop of CF3COOD. Therefore, we found the compounds
in the form of their dicationic triflate salts, showing a twofold
protonation of each imidazole moiety (Figure 2). For compar-
ison, Figure 2 also shows the reported compound L, which was
crystallized as a neutral ligand from the DMF solution. All three
Figure 1. a) The conformational isomerism and tautomerism of L, b) stabilization of the planar ligand configuration by hydrogen contacts in the depicted
conformation, c) the LS and LC conformers of L as found in solution,
[34] d) the coordination of L to metal ions (e.g., FeII) develops the tautomerism-driven
emergence of complexity (schematic representation of the cationic moieties of the isolated isomers of the [2x2] FeII4 grid complexes, consisting of L (black
bars) and FeII ions (grey spheres)).
Scheme 1. Synthesis of the ligands 1 to 6 and the mother compound L (the
first line is only for R=pyrazole derivative; in case of R being a pyridine, refer
to Experimental section), a) K(pyrazolate), diglyme, 110 °C b) NaOH, EtOH/
H2O, 55 °C c) polyphosphoric acid (PPA), 200 °C.
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structures in Figure 2 show the molecules are in the S
configuration (as depicted in Figure 1c).
A detailed examination of the X-ray data shows that the
ligand 3 with indazole derivative is not in planar configuration
in the crystal lattice. The torsion angles are 18° and 24°,
respectively, between the imidazole/pyridine and the pyridine/
indazole subunits. The reason for this torsion is the steric stress
caused by the interaction between the hydrogen atoms of two
opposite aromatic rings, namely the NH hydrogen of the
imidazole and the hydrogen in the 7th position of the indazole
ring. On the other hand, the ligand 5 has a near planar
configuration in the crystal lattice. We calculated a plane out of
all C and N atoms of the ligand backbone. Then we measured
the distance between each carbon and nitrogen atom of the
ligand 5 to this plane, calculating an average distance of 0.05 Å.
The ligands are arranged in layers, and the distance between
two adjacent layers is 3.36 Å. There are also small torsion angles
found for L (13° pyrazole/pyridine and 1° pyridine/imidazole)
and 5 (1° pyridine/pyridine and 6° pyridine/imidazole), but
these are not caused by steric repulsion between H atoms.
We noticed that the protonation state of the ligand has to
be carefully controlled during the workup. Otherwise,
hydrochloride or phosphate adducts can form depending on
the workup procedure. Since these ligands are hardly soluble in
organic solvents that are not miscible with water, it is difficult
to adjust the pH as quickly as could be done easily in a biphasic
system. We suspended the compounds in aqueous/alcoholic
media and changed the pH to the sufficient value (see
experimental section for the preparation of 1·2HCl and 1),
which is time-consuming since it requires time to work with
such an inhomogeneous system. The protonation state of the
final product was assessed by elemental analysis. Furthermore,
the 1H NMR spectroscopic investigations revealed that the
hydrochloride adducts of these ligands 1 to 6 behave slightly
different in solution compared to the free ligands.
As mentioned above, both tauto-conformers of L are
present in solution, and their ratios could be determined by the
integration of the singlet resonances of the central benzene
moieties, Hα, Hβ, and Hγ. In the case of DMSO (deuterated), we
found an equimolar concentration of LS and LC, both in dilute
and concentrated solutions. This is different for the HCl adducts
of such ligands L, 1, 2, 3, and 4, which were precipitated during
the workup under acidic conditions. The 1H NMR spectrum of
1·2HCl adducts (with a concentration of 10 to 20 mM dissolved
in deuterated DMSO) shows just one single resonance for the
central benzene moiety corresponding to Hα. Furthermore,
there is no (or only a very broad) signal for the secondary NH
group at about 12.5 ppm. Apparently, we just found the S form
of the compound from the NMR experiment. A successive
dilution of the sample in 3 steps of one order of magnitude
each is shown in Figure 3 for 1 · 2HCl. The relatively sharp Hα
resonance (Figure 3a) becomes broader after dilution of one
magnitude (Figure 3b) and is almost not visible after the next
dilution step (Figure 3c). At a concentration of about 0.015 mM,
the signals of Hα, Hβ, and Hγ re-appear as it was observed for
the free ligand. This phenomenon was also observed for the
hydrochloride adducts of L, 2, 3, and 4 (see ESI, Figures S2-6).
The coordination reaction of the presented ligands with
transition metal ions such as Fe2+, Co2+, Zn2+ is generally
carried out in solvents like acetonitrile, nitromethane, or
methanol. The solubility of the ligands in these solvents is very
low. Therefore, we can conclude from the 1H NMR spectroscopic
investigation that even for the HCl adducts, both tauto-
conformers are present in solution and a divergent
coordination[34] reaction takes place with at least two main
coordination products. The tautomerization of the ligand is
interesting and gives access to different coordination modes
and products. It is possible to investigate the factors that
Figure 2. Molecular structure of L,[34] 3, and 5 (C black, N green) obtained
from single crystal XRD; the steric repulsion between H atoms of the
imidazole and the indazole subunits in 3 is the reason for the larger torsion
of the aromatic subunits with respect to the other two derivatives L and 5
(see text).
Figure 3. Concentration-dependent 1H NMR spectra of 1 ·2HCl in deuterated
DMSO, at (a) a higher concentration of 15 mM, only the S-conformer is
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influence the isomerization of the formed grid complexes, such
as temperature, solvent polarity, or pH.
However, if we want to study, in detail, the influence of the
different coordination modes on the properties of the coordina-
tion products in the future, it may be advantageous to block
the occurring tautomerization equilibrium of the two different
tauto-conformers of L by chemical substitution at the secondary
amine functionalities forming tertiary amines. The resulting
ligands are either in a C- or S-type conformation which are
unable to tautomerize and can be separated easily by column
chromatography; thus, any parallel product formation is
avoided during divergent coordination protocols. So to block
the interconversion in ligand L, we treated it with alkyl or
benzyl bromides or iodides either in DMF or DMSO as a solvent
in the presence of Cs2CO3 as a base, as depicted in Scheme 2.
The seven pairs of prepared derivatives differ in the steric
demand of the introduced substituents. Increasing the chain
length of the alkyl substituent may influence the crystal packing
of the resulting [2x2] FeII grid complexes in the solid-state and,
therefore, also plays a role in the Spin Crossover (SCO) property
of these compounds as seen before in mononuclear
compounds.[37,38] The synthesized ligands 7C/7S to 13C/13S were
characterized entirely by standard methods like 1H and 13C NMR
spectroscopy, mass spectrometry, and elemental analysis (see
Experimental Section and ESI). It was possible to determine the
molecular structure of 8C, 12C, and 12S by X-ray diffraction of
single crystals (see Figure 4 and Table S2). The substitution of
the secondary amine group of imidazole ring with alkyl and
tert-butylbenzene moieties has improved the solubility of the
ligands in solvents like chloroform/methanol, and even in
diethyl ether in case of 12.
The diverse nature of the prepared derivatives of L will
allow in future a detailed study of different metal complexes
prepared from these structurally related ligands and may
uncover resulting structure-property relationships. As one first
example, we want to report on a Zn4 grid complex prepared
from the reaction of equimolar amounts of L with the metal salt
Zn(ClO4)2 · 6H2O in acetonitrile. The complex formation leads to
a clear yellow solution of a metal complex [Zn4(L)4](ClO4)8. The
1H-NMR spectroscopic investigation of a sample of the reaction
mixture showed 84% of the [Zn4(LS)4]
8+ and 16% of a second
complex, [Zn4(LC)4]8+ isomer, comparing the NMR data with the
data of the FeII grid derivatives described elsewhere.[34] The
second data set of the [Zn4(LC)4](ClO4)8 isomer disappeared after
recrystallization. The major fraction of the reaction product was
isolated by slow diffusion of diisopropyl ether into the
concentrated acetonitrile solution of the complex. The molec-
ular structure of [Zn4(LS)4](ClO4)8 could be determined by X-ray
diffraction of single crystals obtained during this recrystalliza-
tion process (Figure 5b).
So far, it was not possible to isolate the pure [Zn4(LC)4][ClO4]8
isomer since both complexes (C and S) are of same color
whereas in case of the FeII grid complexes, they show differ-
ences in their spin states. Figure 6 shows the 1H NMR spectrum
of the ligand L for comparison, where the C and the S
conformation are in equilibrium, giving, therefore, three signals
for the singlet resonances of the central benzene moieties, Hα,
Hβ, and Hγ
[34] (see Figure 1c and Figure 6) and the spectrum of
[Zn4(LS)4][ClO4]8 showing only one resonance Hα for this moiety.
Besides NMR spectroscopy in solution and X-ray diffraction of
single crystals, we also investigated the properties of
[Zn4(LS)4][ClO4]8 in the gas phase by high-resolution ESI-TOF
mass spectrometry as shown in Figure 7. The mass spectrum of
the reaction mixture following the coordination reaction is
shown in the supporting information but has not such a high
resolution as the one shown in Figure 7.
Scheme 2. Synthesis of the ligand pairs of 7 to 13 starting from the mother
compound L (using either DMSO or DMF as a solvent and Cs2CO3 as a base
for the reaction with the respective haloalkane or benzyl halide, see also the
Experimental Section) different tautomers are chemically stabilized in this
way so that an interconversion is not possible anymore.
Figure 4. X-ray structures of a) 12S, b) 12C, and c) 8C (C black, N green,
hydrogen atoms were omitted for clarity).
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The absorption spectrum of [Zn4(LS)4][ClO4]8 in acetonitrile is
depicted in Figure 8, the absorption maxima (λmax), and
extinction coefficients (ɛ) for the complex are listed in the
supporting information. The UV region of the absorption
spectrum shows strong bands with maxima at 258 nm, 377 nm,
and 394 nm, which corresponds to ligand-centered (LC) π-π*
transition bands. In the free ligand L, these bands are slightly
higher in energy (see SI-Figure S33).
Conclusion
A family of ditopic hexadentate ligands with a central
dihydrobenzo-diimidazole unit based on the mother compound
2,6-bis(6-(pyrazol-1-yl)pyridin-2-yl)-1,5-dihydrobenzo[1,2-d:4,5-
d’]diimidazole (L) were successfully synthesized by condensa-
tion reactions. The two tautomerizing secondary amine func-
tions of the benzodiimidazole unit are the origin of two tauto-
conformers, which can translate into two different isomeric
coordination complexes. We reported on six tautomerizing
derivatives with different nitrogen containing aromatic subunits
with different electronic and steric properties. The resulting
[2x2] grid complexes of transition metals, e. g., FeII, CoII, and the
prepared ligands are interesting in themselves, regarding the
structure-property relationship of the isomeric complexes and
their isomerization equilibrium. The 14 derivatives with different
alkyl and benzyl substitution on secondary amino groups do
not tautomerize and can give access to only one [2x2] grid
Figure 5. a) Schematic representation of the self-assembly process of L and octahedrally coordinating ZnII ions leading to a [2x2] grid-type [Zn4(L)4]8+complex
(ZnII ions: gray spheres), b) Molecular structure of the [Zn4(LS)4]
8+ tauto-conformer was determined by X-ray diffraction (top view, C black, Zn yellow, N blue).
Figure 6. 1H NMR spectra of [Zn4(LS)4][ClO4]8 (bottom) in CD3CN and L (top) in D6-DMSO.
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complex tauto-isomer. In this way, it will be possible to study
the properties of isomeric coordination complexes and their
intrinsic cooperativity on the models of [2x2] grid complexes in
the future. Furthermore, we note that grid complexes built from
the S form of such ligands show two chiral enantiomers. In the
future, we will focus on the deconvolution/separation of these
enantiomers and hope to study their properties in detail.
Experimental Section
General Methods: All the reactions were performed under Argon
atmosphere using standard Schlenk techniques unless specified. All
starting materials were purchased from commercial sources and
were used as received. Solvents were freshly distilled over
appropriate drying reagents. 1H and 13C NMR, COSY, HMQC
correlation measurements were recorded using a Bruker Ultrashield
plus 500 spectrometer with solvent-proton as an internal standard.
Elemental analyses were carried out on a Vario Micro Cube. Infrared
spectra were recorded using KBr-pressed pellets with a Perkin-
Elmer Spectrum GX FT-IR spectrometer in the region of 4000–
400 cm  1. Mass spectrometric data were acquired with a MicroTOF-
Q II Bruker for ESI-TOF. Electronic absorption and fluorescence
spectra were acquired at room temperature for diluted solutions
(e.g., 2×10  6 M) on a Cary 500 Scan UV-VIS-NIR spectrophotometer
and a Cary Eclipse fluorescence spectrophotometer, respectively
using a 1 cm quartz cell. For Zinc complex, Mass-spectrometric
measurements we performed on a SYNAPT G2S-HDMS (Waters,
Manchester, UK) using electrospray ionization.
X-Ray Crystallographic Data: Single crystal X-ray diffraction data
were collected on a STOE IPDS II or IPDS2T diffractometer with
monochromated Mo Kα radiation (0.71073 Å) at low temperatures.
Using Olex2,[39] the structure was solved with the ShelXS[40] structure
solution program using Direct Methods and refined with the
ShelXL[41] refinement package using Least Squares minimization.
Refinement was performed with anisotropic temperature factors for
all non-hydrogen atoms (disordered atoms were refined isotopi-
cally); hydrogen atoms were calculated on idealized positions.
Crystal data and structure refinement parameters are summarized
in Tables S1–S3 in ESI.
Deposition Numbers 1436806 (for L), 1576574 (for 3), 1576575 (for
5), 1576576 (for 8c), 1576577 (for 12c), 1576578 (for 12s), and
1576579 (for [Zn4(LS)4][ClO4]8) contain the supplementary crystallo-
graphic data for this paper. These data are provided free of charge
by the joint Cambridge Crystallographic Data Centre and Fachinfor-
mationszentrum Karlsruhe Access Structures service www.ccdc.ca-
m.ac.uk/structures.
Synthesis of Ligands and Complex
Ligand L: (6-(pyrazol-1-yl)picolinic acid, 4.13 g, 21.8 mmol, 2.1 eq),
1,2,4,5-benzenetetramine tetrahydrochloride (3.00 g, 10.6 mmol, 1
eq), and polyphosphoric acid (20 mL) were gently heated at 130 °C
until the polyphosphoric acid got viscous enough to allow the
stirring with a magnetic stirrer bar. Then the temperature was set
to 200 °C. Caution: gas evolution leads to foam-formation. After 4 h
at 200 °C, the reaction was stopped, allowed to cool below 100 °C
and poured into crushed ice (100 g). The flask was rinsed with
water. The aqueous suspensions were combined. The precipitate
was filtered off. The solid was suspended in water, and the pH
value was altered to 10 using NaOH (3 M). After the suspension was
stirred for 1 h, the precipitate was collected again. Afterwards, it
was suspended again in water, stirred, the pH was set to about 4
using HCl (1 mol/L). The precipitate was washed with MeOH
(125 mL). Finally, the precipitate was suspended in MeOH (100 mL),
stirred overnight, collected by filtration, dried in an oven at 120 °C
for 3 h and then at vacuo (T= 90 °C). Yield: 4.27 g, 73%. 1H NMR
(500 MHz, (CD3)2SO, c=1.3 mM): δ=13.22 (s, very broad, NH), 9.30
(d, 3J=2.3 Hz, 2H, H5), 8.28 (d, 3J=7.1 Hz, 2H, H7), 8.22 (dd (visual
triplet), 3J=7.8 Hz, 3J=7.8 Hz, 2H, H8), 8.05 (d, J=8.0 Hz, 2H, H9),
7.94 (s, very broad, 2H, Hα), 7.93 (d, J=0.9 Hz, 2H, H3), 6.75 (dd, 3J=
2.4 Hz, 3J=1.7 Hz, 2H, H4) ppm. Elemental analysis (EA)
[L*1.5H2O*1.5HCl*0.5CH3OH with 0.5(C49H45N20O4Cl3)0.5 (542.2)]: calc.
C 54.27, H 4.18, N 25.83; found C 54.58, H 4.45, N 25.45. ES-MS (in
DMSO): m/z=467.18 (100%, [M+Na]+). IR (KBr): ~n= 3439, 3099.12,
1641, 1600, 1575, 1521, 1472, 1394, 1339, 1291, 1251,1239, 1203,
1170, 1150, 1137, 1040, 992, 973, 937, 915, 882, 811, 762, 739, 711,
651, 624, 593, 521, 418 cm  1.
Ligand 1·2HCl: (6-(3,5-dimethyl-pyrazol-1-yl)picolinic acid), 3.00 g,
13.8 mmol, 2 eq), 1,2,4,5-benzenetetramine tetrahydrochloride
(1.82 g, 6.42 mmol, 0.93 eq) and polyphosphoric acid (16 mL) were
gently heated at 120 °C until the polyphosphoric acid got viscous
enough to allow the stirring with a magnetic stirrer bar. Then the
temperature was changed gradually to 200 °C (Caution: gas
Figure 7. Mass spectrum of [Zn4(LS)4][ClO4]8. The inset figures respectively
correspond to (a) [(C24N10H15Zn)4]
4+ with a small contribution of (b)
[(C24N10H15Zn)2]
2+, (c) [(C24N10H15Zn)4 -H]
3+ and (d) [(C24N10H15Zn)
4   2H]2+.
Some peaks corresponding to ClO4
  adducts can also be observed at higher
m/z.
Figure 8. Electronic absorption (solid), excitation (dotted), and luminescence
(dashed-dotted, λexc=340 nm) spectra of the [Zn4(LS)4][ClO4]8 complex in
spectroscopic grade CH3CN (c=2.1 μM).
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evolution leads to foam-formation). After 4 hours at 200 °C, the
reaction was stopped, allowed to cool below 100 °C and poured
into crushed ice/water mixture (250 mL). The flask was rinsed with
water. The aqueous suspensions were combined. The grey precip-
itate was slowly filtered off. The solid chunks were suspended in
water by sonication and using a spatula while the pH value was
altered to 9 using NaOH (1 M). After the suspension was stirred for
1.5 h the precipitate was collected again. Afterward, it was
resuspended in water, stirred, the pH was set to about 3 using HCl
(1 mol/L). The compound was suspended in MeOH (V=100 mL),
stirred for 2 h, and collected by filtration. Then the precipitate was
suspended in DMSO (25 mL), stirred for 0.5 h, and collected by
filtration. Yield: 3.14 g, 83%.1H NMR (500 MHz, (CD3)2SO): δ= 12.6
(s, 1.4H, NH, broad), 8.28 (d, 3J=7.5 Hz, 2H, H4), 8.15 (dd, 3J=7.8,
3J=7.8 Hz, 2H, H5), 7.90 (s, 2H, Hα), 7.86 (d,3J=8.0 Hz, 2H, H6), 6.21
(s, 2H, H1), 2.78 (s, 6H, H3), 2.25 (s, 6H, H2) ppm. EA [1*H2O*2HCl
with (C28H28N10OCl2) (591.5)]: calc. C 56.86, H 4.77, N 23.68; found C
56.94, H 5.01, N 23.69. ES-MS (in DMSO): m/z=523.198 (100%, [M+
Na]+ = [(C28H24N10)Na]
+). IR (KBr): ~n=121, 2985, 2925, 1596, 1579,
1523, 1457, 1409, 1387, 1362, 1290, 1239, 1140, 1121, 1060, 1026,
993, 970, 884, 838, 812, 789, 733, 722, 654, 548, 492, 410 cm  1.
Ligand 1: Ligand 1·2HCl (2.88 g) was pestled and suspended in H2O
(30 mL) and MeOH (10 mL). The suspension was stirred and the pH
was adjusted to 7 by using aqueous NaOH (1 mol/L). The pH value
was controlled again after stirring overnight. Finally, the volume
was reduced to 30 mL by rotary evaporation; the precipitate was
collected by filtration, dried in an oven (at 120 °C) over the
weekend. Yield: 2.37 g, 74%. 1: 1H NMR (500 MHz, (CD3)2SO): δ=
12.46 (s, 2H, NH), 12.45 (s, 2H, NH), 8.28 (d, J=7.5 Hz, 4H, H4), 8.14
(dd, 3J=7.8 Hz, 7.8 Hz, 4H, H5), 8.03 (s, 1H, Hβ), 7.85 (s, 4H, H6), 7.83
(s, 2H, Hα), 7.76 (s, 1H, Hγ), 6.21 (s, 4H), 2.77 (s, 12H, CH3, H3), 2.25
(s, 12H, CH3, H2) ppm. EA [1*H2O with (C28H26N10O) (518.58)]: calc. C
64.85, H 5.05, N 27.01; found C 64.57, H 4.64, N 26.78. ES-MS (in
DMSO): m/z=501.218 (100%, [M+H]+ = [(C28H24N10)H]
+), m/z=
523.200 (100%, [M+Na]+ = [(C28H24N10)Na]
+). IR (KBr): ~n=3379,
3121, 2984, 2924, 1648, 1596, 1582, 1559, 1481, 1464, 1446, 1409,
1381, 1363, 1292, 1241, 1140, 1115, 1061, 1030, 989, 971, 886, 849,
812, 774, 723, 656, 632, 591, 497, 419 cm  1.
Ligand 2·HCl: (6-(3,5-diphenyl-pyrazol-1-yl)picolinic acid), 0.763 g,
2.23 mmol, 2 eq), 1,2,4,5-benzenetetramine tetrahydrochloride
(0.284 g, 1.00 mmol, 0.9 eq) and polyphosphoric acid (5 mL) were
used with procedure and workup same as that of synthesis of
Ligand 1·2HCl. Yield: 0.641 g, 80%. 1H NMR (500 MHz, (CD3)2SO, c=
15 mM): δ=12.02 (s, 1.8 H, broad, NH), 8.38 (d, 3J=7.7 Hz, 2H, py-
H4), 8.18 (dd, 3J=7.8, 3J=7.8 Hz, 2H, py-H5), 8.01 (d, 3J=7.2 Hz, 4H,
Ph), 7.75 (s, 2H, broad, Hα), 7.68 (d, 3J=7.8 Hz, 2H, py-H6), 7.51 (dd,
3J=7.6, 3J=7.6 Hz, 4H, Ph), 7.41 (m, 12H, Ph), 7.31 (s, 2H, pz) ppm.
13C-NMR (126 MHz, (CD3)2SO): δ=152.32, 151.99, 150.72, 148.00,
145.68, 141.00, 132.87, 130.78, 129.32, 129.01, 128.94, 128.85,
126.08, 121.48, 121.32, 106.25 ppm. ES-MS (in DMSO): m/z=771.25
(100%, [M+Na]+ = [(C48H32N10)Na]
+). EA [2*H2O*HCl with
(C48H35N10OCl) (803.3)]: calc. C 71.77, H 4.39, N 17.44; found C 71.81,
H 4.32, N 17.27. IR (KBr): ~n=3402, 3059,2968, 1643, 1597, 1577,
1471, 1443, 1424, 1404, 1377, 1361, 1299, 1237, 1198, 1147, 1078,
127, 992, 954, 913, 808, 768, 740, 698, 603, 561, 547, 518 cm1.
Ligand 3·2HCl: (6-(indazol-1-yl)picolinic acid), 1.57 g, 6.61 mmol, 2
eq), 1,2,4,5-benzenetetramine tetrahydrochloride (0.932 g,
3.28 mmol, 2.02 eq), and polyphosphoric acid (8 mL) were used
with procedure and workup same as that of synthesis of Ligand
1·HCl. Yield: 1.51 g, 82%.1H NMR (500 MHz, (CD3)2SO): δ=12.90 (s,
1.8 H, broad, NH), 9.05 (d, 3J=8.5 Hz, 2H, inda), 8.56 (s, 2H, H), 8.32
(d, 3J=7.8 Hz, 2H, pyH8), 8.24 (dd, 3J=7.8, 3J=7.8 Hz, 2H, pyH7),
8.15 (d, 3J=7.8 Hz, 2H, pyH6), 8.02 (s, 2H, bz), 7.98 (d, 3J=8.01 Hz,
2H, inda), 7.74 (dd, 3J=7.25, 7.3 Hz, 1H, inda), 7.44 (dd, 3J=7.3, 3J=
7.3 Hz, 2H, inda) ppm. 13C-NMR (126 MHz, (CD3)2SO): δ=153.97,
151.25, 147.07, 140.87, 138.60, 138.40, 129.04, 126.28, 123.43,
121.74, 119.41, 115.76, 115.35 ppm. ES-MS (in DMSO): m/z=567.18
(100%, [M+Na]+ = [(C32H20N10)Na]
+), 545.17 (20%, [M+H]+ =
[(C32H21N10)]
+). EA [3*H2O*0.5HCl*0.5CH3OH with 1/2(C65H49N20O3Cl)
(596.8)]: calc. C 65.40, H 4.14, N 23.47; found C 65.44, H 3.80, N
23.57. IR (KBr): ~n=3402, 3064, 2603, 1598, 1579, 1459, 1424, 1370,
1351, 1300, 1239, 1197, 1141, 1109, 1073, 1011, 968, 874, 843, 805,
749, 732, 632, 583, 525, 484 cm  1.
Ligand 4·HCl: 6-(4-(4-(tert-butyl)phenyl)-pyrazol-1-yl)picolinic acid
(2.90 g, 9.02 mmol, 2 eq), 1,2,4,5-benzenetetramine tetrahydrochlor-
ide (1.19 g, 4.19 mmol, 0.93 eq) and polyphosphoric acid (20 mL)
were used with procedure and workup same as that of synthesis of
Ligand 1·2HCl. Yield: 2.36 g, 83%. 1H NMR (500 MHz, (CD3)2SO, c=
21 mM): δ=13.01 (s (broad), 2H, NH), 9.65 (s, 2H, H2), 8.41 (s, 2H,
H1), 8.30 (d, J=7.5 Hz, 2H, H3), 8.20 (t, J=7.7 Hz, 2H, H4), 8.05 (d,
J=8.0 Hz, 2H, H5), 7.97 (s (broad), 2H, Hα), 7.85 (d, J=7.4 Hz, 4H,
H6), 7.53 (t, J=7.6 Hz, 4H, H7), 7.36 (t, J=7.3 Hz, 2H, H8) ppm. 13C-
NMR (126 MHz, (CD3)2SO): δ=151.30, 150.81, 147.46, 141.33 (C3),
140.86 (C1), 132.03, 129.52 (C7), 127.57 (C8), 126.04 (C6), 124.97
(C2), 124.91, 119.34 (C3), 112.57 (C5). ES-MS (in DMSO): m/z=
619.19 (50%, [M+Na]+ = [(C36H24N10)Na]
+), (100%, [2 M+Na]+ =
[(C36H24N10)2Na]
+). EA [4*H2O*CH3OH*HCl with (C37H31ClN10O2)
(683.17)]: calc. C 65.05, H 4.57, N 20.50; found C 65.02, H 4.65, N
20.12. IR (KBr): ~n=3112, 1599, 1575, 1473, 1388, 1291, 1234, 1197,
1151, 1103, 1073, 1054, 992, 979, 953, 864, 835, 810, 763, 736, 694,
661, 595, 508 cm  1.
Ligand 5: [2,2’-bipyridine]-6-carboxylic acid (0.703 g, 3.50 mmol, 2
eq), 1,2,4,5-benzenetetramine tetrahydrochloride (0.447 g,
1.57 mmol, 0.9 eq) and polyphosphoric acid (5 mL) were gently
heated to 195 °C (Caution: gas evolution leads to foam-formation).
After 4 h at 195 °C, the reaction was stopped, allowed to cool below
100 °C and poured into 120 mL of water. The resulting melt was
transformed to a powder by sonication and later by stirring. The
precipitate was filtered off. The solid was suspended in water and
the pH value was altered to about 9 using aqueous NH3 (25%). The
product was collected by filtration, washed with water and MeOH.
Finally, it was recrystallized from EtOH. Yield: 0.462 g, 56%. 1H NMR
(500 MHz, (CD3)2SO): δ=13.00 (s, 2H, NH), 12.94 (s, 2H, NH), 9.02
(dd, 3J=13.7 Hz, 3J=7.9 Hz, 4H, H4), 8.8 (d, 4H, H1), 8.52 (dd, 3J=
7.8, 3J=2.1 Hz, 4H, H5), 8.41 (d, 3J=7.4 Hz, 4H, H7), 8.16 (dd, 3J=
11.1, 3J=11.1, 4J=4.5 Hz, 4H, H6), 8.11 (t, 3J=7.6 Hz, 4H, H3), 8.06
(s, 1H, Hβ), 7.91 (s, 2H, Hα), 7.81 (s, 1H, Hγ), 7.56 (dd, 3J=6.8, 3J=
5.4 Hz, 4H, H2) ppm. 13C-NMR (126 MHz, (CD3)2SO): δ=155.11,
155.06, 154.69, 151.55, 151.07, 149.33, 148.10, 142.49, 141.65,
138.65, 137.28, 133.58, 132.73, 124.61, 121.48, 121.38, 121.30,
120.86, 107.85, 99.76 ppm. ES-MS (in DMSO): m/z=467.17 (8%, [M
+H]+), m/z=489.16 (100%, [M+Na]+), m/z=955.32 (27%, [2 M+
Na]+); A [5*3H2O with (C28H24N8O3) (520.6)]: calc. C 64.61, H 4.65, N
21.53; found C 64.82, H 4.84, N 21.27. IR (KBr): ~n= 3203, 3056,1641,
1583, 1566, 1462, 1428, 1391, 1294, 1277, 1240, 1153, 1119, 1052,
994, 968, 884, 827, 783, 745, 710, 686, 635, 622 cm  1.
Ligand 6: 6’-methyl-[2,2’-bipyridine]-6-carboxylic acid (1.00 g,
4.67 mmol, 2.15 eq), 1,2,4,5-benzenetetramine tetrahydrochloride
(0.616 g, 2.17 mmol, 1 eq) and polyphosphoric acid (16 mL) were
used with procedure and workup same as that of synthesis of
Ligand 5. Yield: 0.657 g, 56%. 1H NMR (500 MHz, (CD3)2SO): δ=
12.97 (s, 2H, NH), 12.91 (s, 2H, NH), 8.81 (dd, 3J=13.4, 7.8 Hz, 4H,
H3), 8.51 (dd, J=7.7, 2.3 Hz, 4H, H9), 8.39 (d, J=7.7 Hz, 4H, H11),
8.15 (t, J=7.8 Hz, 4H, H10), 8.05 (s, 1H, Hβ), 7.98 (dd, J=7.7, 7.7 Hz,
4H, H4), 7.89 (s, 2H, Hα), 7.80 (s, 1H, Hγ), 7.42 (d, J=7.6 Hz, 4H, H5),
4.37 (s, 6H, H7) ppm. ES-MS (in DMSO): m/z=517.18 (100%, M+
Na]+ = [C30H22N8Na]
+), m/z=1011.36 (40%, [2 M+Na]+ =
[(C30H22N8)2Na]
+). EA [6*7/3 H2O (536.6)]: calc. C 67.15, H 5.01, N
20.88; found C 67.28, H 4.73, N 20.80. IR (KBr): ~n=3191, 2250, 1636,
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1571, 1452, 1432, 1385, 1315, 1283, 1239, 1167, 1152, 1077, 993,
972, 828, 794, 745, 716, 667, 633, 527, 420 cm  1.
Ligand 7: An oven-dried Schlenk-flask was equipped with a
magnetic stirrer bar and evacuated by three argon-vacuum cycles.
L (0.895 g, 2.02 mmol, 1 eq) and Cs2CO3 (2.64 g, 8.10 mmol, 4 eq)
were added and dried under vacuum at 100 °C overnight. The flask
was flushed with Ar and DMF (40 mL, distilled from CaH2) was
added. After 30 min, the suspension was allowed to cool to
ambient temperature. The iodomethane (0.855 g, 6.06 mmol, 3 eq,
V=0.375 mL) was added using a syringe. After the addition of the
iodomethane the reaction was stopped after 24 h. The DMF was
removed by distillation. The residue was taken into a mixture of
CHCl3/EtOAc and H2O. After phase separation, the aqueous layer
was extracted twice with CHCl3. The organic layer was dried over
Na2SO4, filtered, and reduced to dryness. Then the products were
purified by column chromatography on silica as a stationary phase
and a gradient of CH2Cl2 and MeOH as a liquid phase. Yield: 7S:
0.254 g, 26%, 7 C: 0.221 g, 23%.
Ligand 7S :1H NMR (500 MHz, CDCl3): δ=8.50 (d,
3J=2.4 Hz, 2H,
H5), 8.26 (d, 3J=7.0 Hz, 2H, H7), 8.13 (s, 2H, Hα), 8.09 (d, 3J=7.9 Hz,
2H, H9), 8.05 (t, J=8.0 Hz, 2H, H8), 7.70 (d, 3J=1 Hz, 2H, H3), 6.48
(dd, 3J=2.2 Hz, 3J= 1.8 Hz, 2H), 4.41 (s, 6H, H14) ppm. A better
resolution is observed in CDCl3/CD3OD [5 :1]:
1H NMR (500 MHz,
CDCl3/CD3OD [5 :1], δ(CDCl3)=7.26 ppm): δ=8.52 (d,
3J=2.3 Hz,
2H, H5), 8.13 (t, 3J=4.2 Hz, 2H, H8), 7.97 (d, 3J=4.2 Hz, 4H, H7, H9),
7.74 (s, 2H, Hα), 7.70 (s, 2H, H3), 6.47 (s, 2H, H4), 4.30 (s, 6H, H14)
ppm. 13C NMR (126 MHz, CDCl3/CD3OD [5 :1], δ(CDCl3)=77.16 ppm):
δ=150.70, 150.39, 147.92, 142.34 (C3), 140.07, 139.95 (C7), 135.43,
127.03 (C5), 122.15 (C8), 112.65 (C9), 108.17 (C4), 98.42 (Cα), 32.81
(C14) ppm. EA [7S*H2O with (C26H22N10O) 490.5 g/mol]: calc. C 63.66,
H 4.52, N 28.55; found C 63.91, H 4.47, N 28.84. ES-MS (in DMSO,
DMF, CHCl3): m/z=605.088 (100%, [M+Cs]
+ = [(C26H20N10)Cs]
+ =
605.092). IR (KBr): ~n=3403, 3060, 2924, 2849, 1692, 1593, 1577,
1514, 1475, 1453, 1393, 1368, 1280, 1231, 1201, 1147, 1073, 1034,
948, 896, 763, 810, 752, 653,622, 591 cm  1.
Ligand 7 C: 1H NMR (500 MHz, CDCl3): δ=8.54 (d, J=2 Hz, 2H, H5),
8.24 (d, 3J=7.5 Hz, 2H, H7), 8.15 (s, 1H, Hβ), 7.91 (d, J=8.2 Hz, 2H,
H9), 7.83 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.77 (s, 2H H3), 7.59 (s,
1H, Hγ), 6.55 (m, 2H, H4), 4.41 (s, 6H, H14) ppm. 1H NMR (500 MHz,
CDCl3:CD3OD [5 :1], δ(CDCl3)=7.26 ppm): 8.45 (d,
3J=2.5 Hz, 2H,
H5), 8.10 (dd, 3J=4.9, 3J=3.7 Hz, 2H, H8), 8.04 (s, 1H, Hβ), 7.88 (d,
3J=4.9 Hz, 2H, H7), 7.87 (d,3J=3.6 Hz, 2H, H9), 7.67 (d, 3J=1.5 Hz,
2H, H3), 7.24 (s, 1H, Hγ), 6.44 (dd, 3J =2.5, 3J=1.7 Hz, 2H, H4), 4.24
(s, 6H, H14) ppm. 13C NMR (126 MHz, CDCl3): δ=150.42, 150.36,
148.04, 142.45 (C3), 140.07 (C7), 139.74, 135.92, 127.16 (C5), 122.29
(C8), 112.71 (C9), 108.45(Cβ), 108.27 (C4), 89.25 (Cγ), 33.00 (C14)
ppm. EA [7 C*1/3H2O with
1/3(C78H62N30O) 478.5 g/mol]: calc. C 65.26,
H 4.35, N 29.27; found C 65.01, H 4.47, N 29.16. ES-MS (in DMSO,
DMF, CHCl3): m/z=495.173 (100%, [M+Na]
+ = [(C26H20N10)Na]
+ =
495.177). IR (KBr): ~n= 3395, 3147, 3088, 2942, 1632, 1594, 1575,
1516, 1472, 1456, 1396, 1367, 1337, 1280, 1235, 1202, 1152, 1076,
1037, 950, 899, 842, 810, 773, 619, 592 cm  1.
Ligand 8: The procedure used to prepare ligand 7 was employed
with L (0.895 g, 2.02 mmol, 1 eq), Cs2CO3 (2.64 g, 8.10 mmol, 4 eq),
DMF (30 mL) and bromoethane (0.658 g, 6.06 mmol, 3 eq, V=
0.45 mL) Yield: 8S: 357 mg, 35%, 8 C: 385 mg, 38%.
Ligand 8S: 1H NMR (500 MHz, CDCl3): δ=8.51 (d,
3J=2.5 Hz, 2H,
H5), 8.25 (d, 3J=7.2 Hz, 4J=1.0 Hz, 2H, H7), 8.05 (d, 3J=8.1 Hz, 2H,
H9), 8.02 (t, 3J=7.4 Hz, 2H, H8), 7.82 (s, 2H, Hα), 7.76 (d, 3J=1.2 Hz,
2H, H3), 6.52 (m, 2H, H4), 4.91 (q, 3J=7.1 Hz, 4H, H14), 1.65 (t, J=
7.1 Hz, 6H, H15) ppm. 1H NMR (500 MHz, CDCl3/CD3OD [5 :1],
δ(CDCl3)=7.26 ppm): δ=8.44 (2H, H5), 8.13 (2H, H7), 7.96 (4H, H8,
H9), 7.75 (2H, Hα), 7.68 (2H, H3), 6.45 (2H, H4), 4.82 (4H, H14), 1.58
(6H, H15) ppm. 13C NMR (126 MHz, CDCl3/CD3OD [5 :1], δ(CDCl3)=
77.16 ppm): δ=150.79, 150.25, 148.18, 142.48 (C3), 140.46, 140.09
(C8), 134.46, 127.04 (C5), 122.47 (C7), 112.98 (C9), 108.43 (C4), 98.71
(Cα), 40.81 (C14), 15.09 (C15) ppm. EA [8S*1/2H2O with
1/2(C56H50N20O) 509.6 g/mol]: calc. C 66.00, H 4.95, N 27.49; found C
66.23, H 4.98, N 27.11. ES-MS (in DMSO): m/z= 633.1 (100%, [M+
Cs]+ = [(C28H24N10)Cs]
+). IR (KBr): ~n=3425, 3159, 3100, 2956, 1670,
1596, 1576, 1518, 1473, 1455, 1397, 1374, 1278, 1260, 1200, 1149,
1074, 1042, 994, 947, 906, 834, 807, 770, 732, 653, 423 cm  1.
Ligand 8 C: 1H NMR (500 MHz, CDCl3): δ=8.50 (d,
3J=2.5 Hz, 2H,
H5), 8.37 (d, J=7.6 Hz, 2H, H7), 8.27 (s, 1H, Hβ), 8.03 (d, 3J=8.0 Hz,
2H, H9), 7.93 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.79 (d, 3J=1.0 Hz,
2H, H3), 7.25 (s, 1H, Hγ), 6.54 (dd, 2H, H4), 4.90 (q, 3J=7.1 Hz, 4H,
H14), 1.67 (t, 3J=7.1 Hz, 6H, H15) ppm. 13C NMR (126 MHz, CDCl3):
δ=150.70, 149.50, 148.71, 142.26 (C3), 140.43, 139.63(C8), 135.14,
126.67 (C5), 122.37 (C7), 112.59(C9), 109.78(Cβ), 108.21(C4),
88.28(Cγ), 40.71 (C14), 15.22 (C15) ppm. EA [8 C*1/3 H2O with
1/3(C84H74N30O) 506.6 g/mol]: calc. C 66.39, H 4.91, N 27.65; found C
66.41, H 4.93, N 27.39. ES-MS (in DMSO): m/z=633.1 (100%, [M+
Cs]+ = [(C28H24N10)Cs]
+). IR (KBr): ~n=3430, 3156, 3100, 2956, 1669,
1596, 1576, 1518, 1473, 1456, 1397, 1374, 1278, 1259, 1200, 1149,
1074, 1042, 995, 947, 906, 834, 807, 770, 733, 652 cm  1.
Ligand 9: The reaction was carried out as described for compound
8 using: L (0.895 g, 2.02 mmol, 1 eq), Cs2CO3 (2.65 g, 8.10 mmol, 4
eq), DMSO (20 mL, dried over mole sieves), 1-iodobutane (0.817 g,
4.42 mmol, 2.2 eq, V=0.5 mL). After the addition of the 1-
iodobutane, the reaction was stopped after 21 hours. Yield: 9S:
184 mg, 16%, 9 C: 478 mg, 42%.
Ligand 9S: 1H NMR (500 MHz, CDCl3): δ=8.54 (d,
3J=2.4 Hz, 2H,
H5), 8.38 (d, 3J=7.6 Hz, 2H, H7), 8.10 (d, 3J=8.1 Hz, 2H, H9), 8.02
(dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.86 (s, 2H, Hα), 7.81 (d, 3J=
1.0 Hz, 2H, H3), 6.55 (dd, 3J=2.4 Hz, 3J=1.7 Hz, 2H, H4), 4.93 (t, 3J=
7.6 Hz, 4H, H14), 2.04 (visual quintet, 4H, H15), 1.47 (visual sextet,
4H, H16), 0.97 (t, J=7.4 Hz, 6H, H17) ppm. 1H NMR (500 MHz,
CDCl3/CD3OD [5 :1], δ(CDCl3)=7.26 ppm): δ=8.46 (d, J=2.54 Hz,
2H, H5), 8.18 (dd, 3J=6.4, 3J=2.2 Hz, 2H, H7), 7.99 (m, 4H, H8, H9),
7.78 (s, 2H, Hα), 7.73 (d, J=1.6 Hz, 2H, H3), 6.48 (dd, 3J=2.5 Hz, 3J=
1.7 Hz, 2H, H4), 4.82 (t, 4H, H14), 1.94 (q, 4H, H15), 1.36 (q, 4H, H16),
0.86 (t, 3J=7.4, 3J=7.4 Hz, 6H, H17) ppm. 13C NMR (126 MHz, CDCl3/
CD3OD, 5 :1): δ= 150.74, 150.46, 148.27, 142.50 (C3), 140.23, 140.09
(C8), 134.84, 126.95 (C5), 122.62 (C7), 113.06 (C9), 108.31 (C4), 98.94
(Cα), 45.61 (C14), 32.05 (C15), 20.20 (C16), 13.71 (C17) ppm. EA
[9S*1/2 CH2Cl2 *1/2CH3OH with [1/2(C66H70N20Cl2O)], 615.2 g/mol]:
calc. C 64.43, H 5.74, N 22.77; found C 64.46, H 6.21, N 22.46. ES-MS
(in DMSO): m/z=579.26 (100%, [M+Na]+ = [(C32H32N10)Na]
+), m/z=
689.16 (100%, [M+Cs]+ = [(C32H32N10)Cs]
+). IR (KBr): ~n=3366, 3206,
2955, 2924, 2866, 1688, 1595, 1578, 1520, 1474, 1453, 1395,1324,
1272,1239, 1204, 1154, 1080, 1034, 942, 900, 850, 810, 752 cm  1.
Ligand 9 C: 1H NMR (500 MHz, CDCl3): δ=8.53 (d,
3J=2.4 Hz, 2H,
H5), 8.38 (d, 3J=7.6 Hz, 2H, H7), 8.29 (s, 1H, Hβ), 8.08 (d, 3J=8.1 Hz,
2H, H9), 8.01 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.81 (d, 3J=1.1 Hz,
2H, H3), 7.32 (s, 1H, Hγ), 6.55 (dd, 3J=2.4 Hz, 3J=1.8 Hz, 2H, H4),
4.93 (t, 3J=7.5 Hz, 4H, H14), 2.04 (visual quintet, 4H, H15), 1.46 (m,
4H, H16), 0.99 (t, J=7.4 Hz, 6H, H17) ppm. 13C NMR (126 MHz,
CDCl3): δ=150.76, 149.88, 148.87, 142.39 (C3), 140.32, 139.75 (C8),
135.61, 126.75 (C5), 122.65 (C7), 112.80 (C9), 109.69 (Cβ), 108.20
(C4), 89.06 (Cγ), 45.59 (C14), 32.21 (C15), 20.42 (C16), 14.03 (C17)
ppm. EA [9 C* H2O with [C32H34N10O], 574 g/mol]: calc. C 66.88, H
5.96, N 24.37; found C 67.19, H 5.79, N 24.84. ES-MS (in DMSO):
m/z=557.277 (20%, [M+H]+ = [(C32H32N10)H]
+), m/z=579.259
(100%, [M+Na]+ = [(C32H32N10)Na]
+). IR (KBr): ~n=3392, 3154, 3102,
2956, 2929, 2868, 1633, 1596, 1574, 1519, 1470, 1456, 1395, 1338,
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Ligand 10: The reaction was carried out as described for compound
8 using: L (0.895 g, 2.02 mmol, 1 eq), Cs2CO3 (2.65 g, 8.10 mmol, 4
eq), DMSO (20 mL) and 1-iodohexan (0.856 g, 4.04 mmol, 2 eq, V=
0.528 mL). Yield: 10S: 0.186 g, 16%, 10 C: 0.469 g, 38%.
Ligand 10S: 1H NMR (500 MHz, CDCl3): δ= 8.54 (d,
3J=2.5 Hz, 2H,
H5), 8.38 (d, 3J=7.5 Hz, 2H, H7), 8.10 (d, 3J=8.1 Hz, 2H, H9), 8.02
(dd, 3J=7.9, 3J=7.9 Hz, 2H, H8), 7.86 (s, 2H, Hα), 7.81 (d, 3J= 1.4 Hz,
2H, H3), 6.54 (dd, 3J=2.4 Hz, 3J=1.8 Hz, 2H, H4), 4.92 (t, 3J=7.7 Hz,
4H, H14), 2.06 (q, 4H, H15), 1.45 (q, 4H, H16), 1.31 (m, 8H, H17/H18),
0.85 (t, 3J=7.1 Hz, 6H, H19) ppm. 13C NMR (126 MHz, CDCl3/CD3OD,
5 :1): δ=150.71, 150.45, 148.33, 142.47, 140.32, 140.05 (C8), 134.79,
126.98 (C5), 122.56 (C7), 112.97 (H9), 108.25(C4), 98.88 (Cα), 45.75
(C14), 31.48 (C17), 29.91 (C15), 26.56 (C16), 22.44 (C18), 13.73 (C19)
ppm. EA[10S with [C36H40N10], 612.8 g/mol]: calc. C 70.56, H 6.58, N
22.86; found C 70.42, H 6.72, N 22.81. ES-MS (in DMSO): m/z=
745.25 (100%, [M+Cs]+ = [(C36H40N10)Cs]
+). IR (KBr): ~n=3379, 3221,
3165, 2952, 2926, 2857, 1671, 1594, 1574, 1521, 1475, 1394, 1339,
1274, 1222, 1202, 1152, 1077, 1041, 992, 950, 917, 851, 813, 752,
654, 422 cm  1.
Ligand 10 C: 1H NMR (500 MHz, CDCl3): δ=8.56 (d,
3J=2.5 Hz, 2H,
H5), 8.41 (d, 3J=7.6, 2H, H7), 8.32 (s, 1H, Hβ), 8.11 (d, 3J=8.14 Hz,
2H, H9), 8.03 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.83 (d, 3J=1.1 Hz,
2H, H3), 7.33 (s, 1H, Hγ), 6.57 (dd, 3J=2.5 Hz, 3J=1.7 Hz, 2H, H4),
4.95 (t, 3J=7.5 Hz, 4H, H14), 2.07 (m, 4H, H15), 1.47 (q, 4H, H16),
1.27-1.40 (m, 8H, H17/H18), 0.88 (t, 3J=7.1 Hz, 6H, H19) ppm. 13C
NMR (126 MHz, CDCl3): δ=150.72, 149.91, 148.97, 142.30 (H3),
140.40, 139.71 (C8), 135.57, 126.69 (C5), 122.62 (C7), 112.71 (C9),
109.84 (Cβ), 108.08 (C4), 88.87 (Hγ), 45.72 (C14), 31.60 (C17), 29.97
(C15), 26.75 (C16), 22.57 (C18), 13.97 (C19) ppm. EA [10 C with
[C36H40N10], 612.8 g/mol]: calc. C 70.56, H 6.58, N 22.86; found C
70.40, H 6.68, N 22.85. ES-MS (in DMSO): m/z=745.24 (100%, [M+
Cs]+ = l[(C36H40N10)Cs]
+), 1357.59 (19%, [2 M+Cs]+ =
[(C36H40N10)2Cs]
+). IR (KBr): ~n=3408, 3153, 3078, 2953, 2926, 2856,
1631, 1596, 1573, 1519, 1469, 1394, 1338, 1272, 1222, 1202, 1161,
1081, 1042, 992, 948, 913, 874, 817, 753, 784, 753, 657, 420 cm  1.
Ligand 11: The reaction was carried out as described for compound
12 below. L (1.00 g, 2.25 mmol, 1 eq), Cs2CO3 (2.94 g, 9.00 mmol, 4
eq), DMSO (V=8.5 mL), 3-(bromomethyl)pentane (1.11 g,
6.75 mmol, 3 eq, V=0.944 mL). Yield: 11 C: 0.386 g, 28%, 11S:
0.596 g, 43%.
Ligand 11S: 1H NMR (500 MHz, CD2Cl2): δ= 8.63 (d, 3J=2.4 Hz, 2H,
H5), 8.33 (d,3J=7.5 Hz, 4J=1 Hz, 2H, H7), 8.12 (d, 3J=8.2 Hz, 4J=
1 Hz, 2H, H9), 8.06 (dd,3 J=7.6 Hz, 3 J=8.1 Hz, 2H, H8), 7.86 (s, 2H,
bz, Hα), 7.82 (d, J=2 Hz, 2H, H3), 6.59 (dd, 3J=2.5 Hz, 3J=1.7 Hz,
2H, H4), 5.01 (d, 3J=7.7 Hz, 4H, H14), 2.00 (ttt, 2H, H15), 1.32 (m, 8H,
H16), 0.82 (t, 3J =7.5 Hz, 12H, H17) ppm. 13C NMR (126 MHz,
CD2Cl2): δ=150.85, 150.68, 149.52, 142.16 (C3), 140.94, 139.70 (C8),
135.31, 126.83(C5), 122.59(C7), 112.53 (C9), 108.00 (C4), 99.54 (Cα),
48.90 (C14), 40.91 (C15), 23.33 (C16), 10.45 (C17) ppm. EA [11S*1/3
H2O with [1/3(C108H122N30O)], 618.34 g/mol]: calc. C 69.88, H 6.62, N
22.64; found C 69.93, H 6.54, N 22.48. ES-MS (in DMSO): m/z=
745.22 (100%, [M+Cs]+ = [(C36H40N10)Cs]
+). IR (KBr): ~n=3415, 3103,
2960, 2931, 2873, 1592, 1573, 1520, 1469, 1396, 1337, 1273, 1248,
1203, 1177, 1153, 1076, 1040, 946, 880, 809, 753, 654 cm  1.
Ligand 11 C: 1H NMR (500 MHz, CD2Cl2): δ=8.63 (d,
3J=2.4 Hz, 2H,
H5), 8.34 (d, 3J=7.5 Hz, 4J=1.0 Hz, 2H, H7), 8.17 (s, 1H, Hβ), 8.11 (d,
3J=8.2, 4J=1.0 Hz, 2H, H9), 8.06 (dd, 3J=7.7 Hz, 3J=8.0 Hz, 2H, H8),
7.82 (d, 3J=1.2 Hz, 2H, H3), 7.42 (s, 1H, Hγ), 6.59 (dd,3J=2.4, 1.8 Hz,
2H, H4), 5.01 (d,3J=7.6 Hz, 4H, H14), 1.96 (ttt, 2H, H15), 1.33 (m, 8H,
H16), 0.82 (t, 3J=7.5 Hz, 12H, H17) ppm. 13C NMR (126 MHz, CD2Cl2):
δ= 150.65, 150.44, 149.50, 142.14 (C3), 140.35, 139.72 (C8), 135.79,
126.79 (C5), 122.60(C7), 112.51 (C9), 109.20 (Cβ), 107.95 (C4), 90.25
(Cγ), 48.77(C14), 41.14(C15), 23.40(C16), 10.53(C17) ppm. EA [11 C
with (C36H40N10) 612.79 g/mol]: calc. C 70.56, H 6.58, N 22.86; found
C 22.61, H 6.61, N 22.61. ES-MS (in DMSO): m/z=745.22 (100%, [M
+Cs]+ = [(C36H40N10)Cs]
+). IR (KBr): ~n=3430, 3104, 2961, 2931, 2874,
1594, 1574, 1519, 146, 1394, 1338, 1273, 1250, 1201, 1181, 1150,
1077, 1037, 944, 881, 811, 752, 662.
Ligand 12: The reaction was carried out as described for compound
8 using: L (0.895 g, 2.02 mmol, 1 eq), Cs2CO3 (2.65 g, 8.10 mmol, 4
eq), DMSO (20 mL, dried over mole sieves), 1-(bromomethyl)-3,5-di-
tert-butylbenzene (1.73 g, 6.06 mmol, 3 eq). Yield: 12 C 0.752 g,
42%, 12S 0.782 g, 46%.
Ligand 12 C: 1H NMR (500 MHz, CD2Cl2): δ=8.40 (d, 3J=6.2, 4J=
2.43 Hz, 2H, py), 8.29 (s, 1H, bz), 8.02 (m, 2H+2H, py), 7.67 (d, 3J=
1.6 Hz, 2H, pz), 7.52 (d, 3J=2.5, 2H, pz), 7.36 (s, 2H, dtbb), 7.33 (s,
1H, bz), 7.08 (s, 4J=1.7 Hz, 4H, dtbb), 6.23 (dd, 3J=2.5, 3J=1.7 Hz,
2H, pz), 6.03 (s, 4H, CH2), 1.20 (s, 36H, tb-CH3) ppm.
13C NMR
(126 MHz, CD2Cl2): δ=151.69, 151.04, 149.05, 142.25, 141.06,
140.02, 136.70, 136.52, 127.50, 122.51, 121.64, 120.76, 112.69,
109.90, 108.09, 90.07, 49.99, 35.04, 31.48 ppm. EA [12 C with
(C54H60N10), 849.14 g/mol]: calc. C 76.38, H 7.12, N 16.50; found C
76.54, H 7.33, N 16.81. ES-MS (in DMSO): m/z=871.479 (100%, [M+
Na]+ = [(C54H60N10)Na]
+). IR (KBr): ~n=3417, 3102, 2961, 2867, 1596,
1574, 1520, 1469, 1394, 1372, 1275, 1250, 1201, 1164, 1074, 1038,
994, 943, 885, 810, 751, 711, 662 cm  1.
Ligand 12S: 1H NMR (500 MHz, CDCl3): δ=8.30 (d,
3J=7.4 Hz, 2H,
py, H7), 8.04 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, py, H9), 8.00 (dd, 3J=
7.8, 3J=7.8 Hz, 2H, py, H8), 7.83 (s, 2H, bz, Hα), 7.69 (d, 2H, pz, H5),
7.68 (d, J=2.5 Hz, 2H, pz, H3), 7.33 (s, 2H, dtbb, H17), 7.05 (s, 4H,
dtbb, H15), 6.22 (m, 2H, pz, H4), 6.09 (s, 4H, CH2, H14), 1.19 (s, 36H,
tb-CH3, H19) ppm.
13C NMR (126 MHz, CDCl3): δ=151.29, 151.18,
150.66, 148.50, 142.10 (pz), 141.11, 139.74 (py), 135.95, 135.34,
127.26 (pz), 122.07 (py), 121.33 (dtbb), 120.28 (dtbb), 112.48 (py),
107.84 (pz-9), 99.85 (bz), 49.72 (CH2), 34.76(tbu-C(CH3)), 31.36(tbu-
CH3) ppm. EA [12S*1/3 H2O with [1/3(C162H182N30O)], 855.15 g/mol]:
calc. C 75.85, H 7.15, N 16.38; found C 75.96, H 6.87, N 16.55. ES-MS
(in DMSO): m/z=871.478 (100%, [M+Na]+ = [(C54H60N10)Na]
+). IR
(KBr): ~n=3425, 3088, 3954, 2866, 1596, 1574, 1518, 1470, 1417,
1396, 1372, 1276, 1250, 1201,1162, 1077, 1040, 995, 945, 885, 832,
810, 759, 712 cm  1.
Ligand 12: The reaction was carried out as described for compound
8 using: L (0.895 g, 2.02 mmol, 1 eq), Cs2CO3 (2.65 g, 8.10 mmol, 4
eq), DMF (30 mL), 1-bromo-2-methoxyethane (0.838 g, 6.06 mmol, 3
eq, V=0.566 mL). Yield: 12 C 0.752 g, 42%, 12S 0.782 g, 46%.
Ligand 13 C: 1H NMR (500 MHz, CDCl3): δ= 8.56 (d,
3J=2.5 Hz, 2H,
H5),8.40 (d, 3J=7.7, 2H, H7), 8.22 (s, 1H, Hβ), 8.02 (d, J=8.1 Hz, 2H,
H9), 7.92 (dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.79 (d, J=1.1 Hz, 2H,
H3), 7.48 (s, 1H, γ), 6.54 (dd, 3J=2.5 Hz, 3J=1.6 Hz, 2H, H4), 5.05 (t,
3J=6.6 Hz, 4H, H14, CH2), 3.96 (t,
3J=6.6 Hz, 4H, H15, CH2), 3.38 (s,
6H, H16, CH3) ppm.
13C NMR (126 MHz, CDCl3): δ=150.68, 149.54,
148.61, 142.41 (C3), 140.32, 139.80 (C8), 136.15, 126.99 (C5), 122.43
(C7), 112.81 (C9), 109.48 (Cβ), 108.39 (C4), 89.91 (Cγ), 71.53 (C15),
59.27 (C16), 45.59 (C14) ppm. EA [13 C*1/3EtOAc with [1/
3(C94H92N30O8) 589.99 g/mol]]: calc. C 63.79, H 5.24, N 23.74; found C
64.02, H 5.62, N 23.34. ES-MS (in DMSO): m/z=561.237 (55%, [M+
H]+ = [(C30H28N10O2)H]
+), 583.219 (100%, [M+Na]+ = [(C30H28N10O2)
Na. IR (KBr): ~n=3375, 3413, 3104, 2986, 2897, 1729, 1628, 1595,
1573, 1521, 1470, 1395, 1374, 1338, 1327, 1277, 1202, 1150, 1114,
1077, 1042, 994, 946, 906, 869, 811, 754, 660 cm  1.
Ligand 13S: 1H NMR (500 MHz, CDCl3): δ=8.63 (d, 3J=2.5 Hz, 2H,
H5), 8.42 (d, 3J=7.40 Hz, 2H, H7), 8.10 (d, 3J=8.13 Hz, 2H, H9), 8.02
(dd, 3J=7.9 Hz, 3J=7.9 Hz, 2H, H8), 7.94 (s, 2H, Hα), 7.80 (d, 3J=
1.2 Hz, 2H, H3), 6.55 (dd, 3J=2.5, 3J=1.7 Hz, 2H, H4), 5.12 (t, 3J=
6.6 Hz, 4H, H14, CH2), 3.99 (t,
3J=6.6 Hz, 4H, H15, CH2), 3.37 (s, 6H,
H16, CH3) ppm.
13C NMR (126 MHz, CDCl3): δ=150.86, 150.26,
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148.40, 142.38 (C3), 140.63, 139.83 (C8), 135.46, 127.02 (C5), 122.50
(C7), 112.95 (C9), 108.36 (C4), 99.33 (Cα), 71.13 (C15), 59.15 (C16),
45.44 (C14) ppm. EA [13S *1/3EtOAc with [1/3(C94H92N30O8)
589.99 g/mol)]: calc. C 63.79, H 5.24, N 23.74; found C 63.97, H 5.63,
N 23.44. ES-MS (in DMSO): m/z=561.236 (55%, [M+H]+ =
[(C30H28N10O2)H]
+), 583.219 (100%, [M+Na]+ = [(C30H28N10O2)Na]
+).
IR (KBr): ~n=3422, 3140, 3108, 2925, 289, 1742, 1594, 1574, 1510,
1471, 1455, 1395, 1372, 1338, 1279, 1248, 1200, 1150, 1118, 1074,
1040, 948, 906, 812, 754, 656 cm  1.
[Zn4(L)4](ClO4)8: The ligand L (0.050 g, 0.11 mmol, 1 eq.) was
suspended in CH3CN (50 mL). Afterwards, a solution of Zn-
(ClO4)2 · 6H2O (0.042 g, 0.11 mmol, 1 eq.) dissolved in CH3CN (10 mL)
was added. The reaction was heated at 70 °C for 48 h. It was
allowed to cool to room temperature and filtered. The filtrate was
reduced to about 15 mL. Diisopropyl ether (DIPE) diffused into the
acetonitrile solution which led to yellow crystals. Yield: 0.059 g,
74%. 1H-NMR (500 MHz, CD3CN): δ=12.12 (2H, s, NH), 8.74 (2H, dd,
3J=8.1, 3J=8.2, pyridine), 8.57 (2H, d, J=2.7 Hz, pyrazole), 8.36 (2H,
d, J=7.8 Hz, pyridine), 8.25 (2H, d, J=8.5 Hz, pyridine), 7.40 (2H, d,
J=1.9 Hz, pyrazole), 6.64 (s, 2H, benzimidazole), 6.52 (dd, 2H, J=
2.1 Hz, J=2.6 Hz, pyrazole) ppm. 13C-NMR (126 MHz, CD3CN) δ=
150.2, 147.9, 147.4 (pyridine), 143.8 (pyrazole), 141.4, 138.3, 134.4,
130.8 (pyrazole), 121.4 (pyridine), 115.7 (pyridine), 112.1 (pyrazole),
100.9 (benzimidazole) ppm. High-resolution ES-MS: m/z=507.081
(100%, [M-4H-8 ClO4]
4+ = [(C24N10H15Zn)4]
4+), 675.766 (73.7%, [M-
5H-8 ClO4]
3+ = [(C24N10H15Zn)4-H]
3+), 1013.140(8.9%, [M-6H-8 ClO4]
2+
= [(C24N10H15Zn)4-2H]
2+. EA [1*2HClO4*2(C3H7)2O with
C108H94Cl10N40O42Zn4 (3240.20)]: calc. C 40.03, H 2.92, N 17.29; found
C 40.00, H 2.62, N 17.01. UV/Vis: λ(ɛmax /10  3 M  1 cm  1)=200 (188),
222 (sh 122), 258 (108), 301 (44), 377 (167), 394 (162), 432 (sh 35)
nm. IR (KBr): ~n=1617, 1588, 1530, 1496, 1452, 1398, 1317, 1246,
1106, 1052, 986, 806, 764, 624 cm  1.
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